K. Rau

K. Rau, Chia-Chin Lin, Shu-Yi Wang, 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

Integrin αIIbβ3 outside-in signaling activates human platelets through serine 24 phosphorylation of Disabled-2

K. Rau, Ding-Ping Chen, Yi-Hsuan Chiang, 2021, Cell & bioscience.

High p16 expression predicts a positive response to chemoradiotherapy in stage IVa/b head and neck squamous cell carcinoma.

K. Rau, F. Fang, C. Chien, 2011, Asian Pacific journal of cancer prevention : APJCP.

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.

K. Rau, Chih-Hung Hsu, Chung-Pin Li, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Weekly paclitaxel combining with gemcitabine is an effective and safe treatment for advanced breast cancer patients.

K. Rau, Shan Li, Yen-Yang Chen, 2011, Japanese journal of clinical oncology.

Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors

K. Rau, M. Su, T. Chao, 2016, BMC Cancer.

Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response

K. Rau, C. Tseng, Yu-Li Su, 2020, Journal of clinical medicine.

A nationwide survey of fatigue in cancer patients in Taiwan: an unmet need

K. Rau, K. Yeh, C. Lu, 2020, Japanese journal of clinical oncology.

Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell Carcinoma

K. Rau, S. Luo, T. Chiu, 2015, BioMed research international.

EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid.

Dar-Ren Chen, King-Jen Chang, K. Rau, 2014, In vivo.

Gender Difference in Cancer Patients’ Adherence to Analgesics and Related Outcomes of Pain Management

K. Rau, Su-Ying Fang, Bih-O Lee, 2017, Cancer nursing.

A preliminary randomised controlled study of short-term Antrodia cinnamomea treatment combined with chemotherapy for patients with advanced cancer

K. Rau, Yu-Chiang Hung, Yu-Li Su, 2016, BMC Complementary and Alternative Medicine.

Quality of life assessment in Taiwanese patients with bone metastases from breast cancer receiving zoledronic acid.

Dar-Ren Chen, King-Jen Chang, K. Rau, 2013, Anticancer research.

Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?

K. Rau, R. Cheng, S. Rajappa, 2022, World journal of hepatology.

Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study

A. Khorana, E. Gallardo, E. Macias, 2018, Journal of thrombosis and haemostasis : JTH.

Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin‐based chemotherapy

K. Rau, Yu-Li Su, Yen-Yang Chen, 2016, International journal of urology : official journal of the Japanese Urological Association.

Metastatic Urothelial Carcinoma of the Bladder with Lymph Node-only Metastasis Treated with M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) has a Better Survival than GC (Gemcitabine and Cisplatin)

K. Rau, Yen-Yang Chen, Cheng-Hua Huang, 2014 .

Chromogranin A Is a Reliable Biomarker for Gastroenteropancreatic Neuroendocrine Tumors in an Asian Population of Patients

T. Hwang, K. Rau, C. Lu, 2012, Neuroendocrinology.

K. Rau, Chuan-Chao Wang, Jen‐Shi Chen, 2017, Japanese journal of clinical oncology.

Trousseau's syndrome in a patient with advanced stage gastric cancer.

K. Rau, Keng-Liang Wu, S. Chuah, 2015, World journal of gastroenterology.

Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α-fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study.

M. Kudo, P. Galle, G. Gerken, 2019, Journal of Clinical Oncology.

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Yan-Shen Shan, Paul Ross, Daniel Palmer, 2016, The Lancet.

Incidence of ischemic stroke post-chemotherapy: A retrospective review of 10,963 patients

K. Rau, Shau-Hsuan Li, Yen-Yang Chen, 2006, Clinical Neurology and Neurosurgery.

Impact of Prognostic Nutritional Index on Overall Survival for Patients with Metastatic Urothelial Carcinoma

K. Rau, Chun-Chieh Huang, Cheng-Hua Huang, 2018, Journal of Cancer.

Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan

Dar-Ren Chen, K. Rau, M. Hou, 2018, Breast Cancer Research and Treatment.

The ALBI grade predicts the prognosis of patients with advanced hepatocellular carcinoma received sorafenib

K. Rau, Sheng-Nan Lu, Chien-Hung Chen, 2017 .

Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): pooled results from two phase 3 studies (REACH and REACH-2)

M. Kudo, P. Galle, K. Rau, 2020, Zeitschrift für Gastroenterologie.

Impact of Undertreatment of Cancer Pain With Analgesic Drugs on Patient Outcomes: A Nationwide Survey of Outpatient Cancer Patient Care in Taiwan.

K. Rau, C. Yen, Kuan-Der Lee, 2017, Journal of pain and symptom management.

Development and validation of the Chinese Version of Spiritual Interests Related Illness Tool for patients with cancer in Taiwan.

K. Rau, Yu-Ling Lin, Yu-hua Lin, 2015, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

M. Kudo, P. Galle, G. Gerken, 2019, The Lancet. Oncology.

Midkine neurite growth-promoting factor 2 expression as a potential prognostic marker of adjuvant therapy in head and neck squamous cell carcinoma

K. Rau, C. Chien, Shau-Hsuan Li, 2013, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers.

M. Hung, K. Rau, Tai‐Lung Cha, 2005, Endocrine-related cancer.

Impact of combined hospice care on terminal cancer patients.

K. Rau, Chih-Fang Huang, S. Loke, 2011, Journal of palliative medicine.

Proteomic analysis reveals tanshinone IIA enhances apoptosis of advanced cervix carcinoma CaSki cells through mitochondria intrinsic and endoplasmic reticulum stress pathways

K. Rau, Chun-Hsun Huang, Yu-Chiang Hung, 2013, Proteomics.

High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy

K. Rau, F. Chou, T. Chiu, 2017, Molecular medicine reports.

Breast cancer gene therapy

M. Hung, K. Rau, Chi-Ping Day, 2006 .

Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation.

K. Rau, S. Tsai, Tzong-Der Way, 2010, Journal of agricultural and food chemistry.

Comparative Study of Esophageal Stent and Feeding Gastrostomy/Jejunostomy for Tracheoesophageal Fistula Caused by Esophageal Squamous Cell Carcinoma

K. Rau, Y. Chiu, Shau-Hsuan Li, 2012, PloS one.

Mesentery solitary fibrous tumor with postoperative recurrence and sarcomatosis: A case report and review of literature

K. Rau, C. Chiu, Y. Yonemura, 2022, World journal of clinical oncology.

Cancer-specific activation of the survivin promoter and its potential use in gene therapy

Yung‐Chie Lee, King-Jen Chang, M. Hung, 2004, Cancer Gene Therapy.

Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma.

K. Rau, Wei-Che Lin, Shau-Hsuan Li, 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study

K. Rau, Kuan-Der Lee, Jen‐Shi Chen, 2015, BMC Cancer.

Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers.

K. Rau, T. Chiu, Chao-Cheng Huang, 2012, Experimental and therapeutic medicine.

Taiwan nutritional consensus on the nutrition management for gastric cancer patients receiving gastrectomy.

K. Rau, Deng-Chyang Wu, Jaw-Town Lin, 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens

P. Ang, K. Rau, M. Hou, 2021, Breast Cancer Research and Treatment.

Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance.

Y. Jan, K. Rau, C. Yeh, 2011, World journal of gastroenterology.

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

J. Desai, K. Rau, M. Friedlander, 2020, Journal for immunotherapy of cancer.

Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis

K. Rau, Chao-Cheng Huang, Chin-Chou Wang, 2016, International journal of molecular sciences.

Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI‐1 study

Joon-Oh Park, Y. Bang, K. Rau, 2019, Cancer science.

Asthma and Risk of Prostate Cancer

K. Rau, Yu-Li Su, Charles Tzu-Chi Lee, 2015, Medicine.

Prognostic effects and regulation of activin A, maspin, and the androgen receptor in upper urinary tract urothelial carcinoma.

K. Rau, Yi-Ju Chen, Hong-Yo Kang, 2011, Anticancer research.

Comparative Study of the Safety and Efficacy of First-Line Cisplatin and Carboplatin Chemotherapy in Elderly Patients with Metastatic Urothelial Carcinoma

K. Rau, Jui-Ming Liu, Shi-Yu Huang, 2019, Oncology.

Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma

K. Rau, Yu-Li Su, Jui Lan, 2017, PloS one.

Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma

K. Rau, Wei-Che Lin, Shau-Hsuan Li, 2015, Journal of the renin-angiotensin-aldosterone system : JRAAS.

A Novel Combination of Bevacizumab with Chemotherapy Improves Therapeutic Effects for Advanced Biliary Tract Cancer: A Retrospective, Observational Study

K. Rau, C. Hung, C. Chiu, 2021, Cancers.

A Prognostic Model Using Inflammation- and Nutrition-Based Scores in Patients With Metastatic Gastric Adenocarcinoma Treated With Chemotherapy

K. Rau, S. Chuah, Yu-Hung Lin, 2016, Medicine.

KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): The TCOG T1210 trial

K. Rau, Chiun Hsu, Y. Chao, 2013 .

S-1 versus Doublet Regimens as Adjuvant Chemotherapy in Patients with Advanced Gastric Cancer after Radical Surgery with D2 Dissection—A Propensity Score Matching Analysis

K. Rau, Yen-Yang Chen, Chung-Yen Chen, 2020, Cancers.

Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy

Chiun-Sheng Huang, Ching-Hung Lin, Tiffany Ting-Fang Shih, 2015, Clinical Cancer Research.

Extrapulmonary small cell carcinoma--a medical center's experience.

K. Rau, Yen-Yang Chen, Tai‐Lin Huang, 2006, Chang Gung medical journal.

Patients with head and neck cancer may need more intensive pain management to maintain daily functioning: a multi-center study

K. Rau, C. Yen, Kuan-Der Lee, 2018, Supportive Care in Cancer.

Potential and role of artificial intelligence in current medical healthcare

K. Rau, C. Chiu, Hui-Ming Lee, 2022, WArtificial Intelligence in Cancer.

A nationwide survey of adherence to analgesic drugs among cancer patients in Taiwan: prevalence, determinants, and impact on quality of life

K. Rau, C. Yen, C. Lu, 2018, Supportive Care in Cancer.

Mutant Bik expression mediated by the enhanced minimal topoisomerase IIα promoter selectively suppressed breast tumors in an animal model

G. Hortobagyi, M. Hung, K. Rau, 2006, Cancer Gene Therapy.

Effects of physical activity on the quality of life in taiwanese lung cancer patients receiving active treatment or off treatment.

K. Rau, Yu-Chung Wu, Chia-chin Lin, 2013, Cancer nursing.

Longitudinal study on the impact of physical activity on the symptoms of lung cancer survivors

K. Rau, Chia-chin Lin, Yi-Yun Lin, 2015, Supportive Care in Cancer.

Truth telling in Taiwanese cancer care: patients' and families' preferences and their experiences of doctors' practices

K. Rau, C. Fang, Y. Juang, 2017, Psycho-oncology.

The effects of hospice-shared care for gastric cancer patients

K. Rau, S. Chuah, Yu-Hung Lin, 2017, PloS one.

Glypican-3 Expression in Breast Cancer

S. Sheen-Chen, K. Rau, Chao-Cheng Huang, 2015 .

Phase I dose escalation study of oxaliplatin combined with oral tegafur–uracil and leucovorin in patients with advanced gastric cancer

Hung-Ming Wang, K. Rau, Jen‐Shi Chen, 2005, Anti-cancer drugs.

Upper gastrointestinal bleeding as the initial manifestation of lung adenocarcinoma metastatic to the stomach

K. Rau, Y. Chiu, Shau-Hsuan Li, 2007 .

Presence of Chronic Obstructive Pulmonary Disease (COPD) Impair Survival in Lung Cancer Patients Receiving Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI): A Nationwide, Population-Based Cohort Study

K. Rau, Yen-Yang Chen, Jia-Sin Liu, 2019, Journal of clinical medicine.

Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms

K. Rau, Keng-Liang Wu, S. Chuah, 2018, The Kaohsiung journal of medical sciences.

A Survival Scoring System for Non-Small Cell Lung Cancer Patients with De Novo Bone Metastases

K. Rau, M. Su, Yung-Che Chen, 2016, PloS one.

Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors.

K. Rau, M. Su, Yung-Che Chen, 2016, Lung cancer.

The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.

K. Rau, Yu-Li Su, Yen-Yang Chen, 2015, Urologic oncology.

The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis

K. Rau, Sheng-Nan Lu, Chien-Hung Chen, 2018, Investigational New Drugs.

Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study

K. Rau, C. Chiu, Yu-Li Su, 2021, Journal of Cancer.

Increased cumulative doses and appearance of hand‐foot skin reaction prolonged progression free survival in sorafenib‐treated advanced hepatocellular carcinoma patients

K. Rau, Sheng-Nan Lu, Wen-Tsan Chang, 2018, The Kaohsiung journal of medical sciences.

Karnofsky Performance Status as A Predictive Factor for Cancer-Related Fatigue Treatment with Astragalus Polysaccharides (PG2) Injection—A Double Blind, Multi-Center, Randomized Phase IV Study

K. Rau, Jen‐Shi Chen, Chieh-Fang Cheng, 2019, Cancers.

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression

K. Rau, Tae-You Kim, Joong-Won Park, 2021, British Journal of Cancer.

A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors

J. Desai, K. Rau, M. Friedlander, 2018, Annals of Oncology.

Albumin‐Bilirubin grade predicts prognosis of HCC patients with sorafenib use

K. Rau, Sheng-Nan Lu, Chien-Hung Chen, 2017, Journal of gastroenterology and hepatology.

Development and psychometric testing of a short version of the Barriers Questionnaire-Taiwan form for cancer patients.

K. Rau, Pi-Ling Chou, Chia-chin Lin, 2011, International journal of nursing studies.

Intra-Arterial Chemotherapy with Doxorubicin and Cisplatin Is Effective for Advanced Hepatocellular Cell Carcinoma

K. Rau, Sheng-Nan Lu, Chi-Chih Wang, 2014, TheScientificWorldJournal.

Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy.

K. Rau, K. Yeh, Kuan-Der Lee, 2016 .

Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC).

J. Kim, K. Rau, C. Yen, 2018, Annals of Oncology.

Adding bevacizumab to chemotherapy effectively control radioresistant brain metastases in ALK-positive lung adenocarcinoma.

K. Rau, Yu-Li Su, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.

Ying Cheng, K. Rau, Jun Liang, 2014, The oncologist.

Correspondence to 'Treatment of PERItoneal disease in Stomach Cancer with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: PERISCOPE I initial results'.

K. Rau, C. Hung, C. Chiu, 2020, The British journal of surgery.

Divergent Roles of Induction Chemotherapy in Patients with Unresectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Population-Based Matched Cohort Study

K. Rau, Meng-Che Hsieh, Chuan-Chien Yang, 2021, SSRN Electronic Journal.

A Phase II study of S-1 plus oral leucovorin in heavily treated metastatic colorectal cancer patients

K. Rau, Kuan-Der Lee, W. Chou, 2018, Cancer management and research.

A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma

K. Rau, Chiun Hsu, W. Yeo, 2014, Clinical Cancer Research.

K. Rau, M. Su, T. Chao, 2016, BMC Cancer.

Occurrence, severity, and impact of cancer-related fatigue in Taiwanese patients with cancer: A national survey.

K. Rau, S. Shun, Yung-Chuan Sung, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A comparative study of isolated and metachronous oesophageal squamous cell carcinoma with antecedent upper aerodigestive tract cancer.

K. Rau, Wei-Che Lin, F. Fang, 2013, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Management of cancer-related fatigue in Taiwan: an evidence-based consensus for screening, assessment and treatment

K. Rau, S. Shun, Li-Yun Tsai, 2022, Japanese journal of clinical oncology.

Propensity for home death among Taiwanese cancer decedents in 2001-2006, determined by services received at end of life.

K. Rau, S. Tang, Shiao-Chi Wu, 2010, Journal of pain and symptom management.

Trimodality Treatment for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma

K. Rau, Y. Chiu, Shau-Hsuan Li, 2011 .

Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients.

S. Thongprasert, K. Rau, S. Ye, 2010 .

Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).

M. Kudo, K. Rau, R. Finn, 2019, Journal of Clinical Oncology.

An evaluation of focal adhesion kinase in breast cancer by tissue microarrays.

S. Sheen-Chen, K. Rau, Chun-Ying Huang, 2013, Anticancer research.